Qsymia's US approval set to fatten revenues at Taiwan's ScinoPharm
This article was originally published in Scrip
The recent US FDA approval of Vivus' anti-obesity drug Qsymia is having knock-on effects half a world away in Asia, where one of the US firm's key active pharmaceutical ingredient (API) suppliers is girding itself to meet expected demand.
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context